JP2018531914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531914A5 JP2018531914A5 JP2018513505A JP2018513505A JP2018531914A5 JP 2018531914 A5 JP2018531914 A5 JP 2018531914A5 JP 2018513505 A JP2018513505 A JP 2018513505A JP 2018513505 A JP2018513505 A JP 2018513505A JP 2018531914 A5 JP2018531914 A5 JP 2018531914A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tgf
- antagonist
- combination
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000005557 antagonist Substances 0.000 claims description 164
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 100
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 100
- 206010028980 Neoplasm Diseases 0.000 claims description 81
- 201000011510 cancer Diseases 0.000 claims description 81
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 72
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 72
- 239000012634 fragment Substances 0.000 claims description 37
- 108091005735 TGF-beta receptors Proteins 0.000 claims description 32
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 32
- 230000028993 immune response Effects 0.000 claims description 32
- 230000005867 T cell response Effects 0.000 claims description 30
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 150000001413 amino acids Chemical group 0.000 claims description 15
- 108020001507 fusion proteins Proteins 0.000 claims description 14
- 102000037865 fusion proteins Human genes 0.000 claims description 14
- 230000002708 enhancing effect Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000037455 tumor specific immune response Effects 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims 7
- 108020003175 receptors Proteins 0.000 claims 7
- 238000000034 method Methods 0.000 description 60
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562218227P | 2015-09-14 | 2015-09-14 | |
| US201562218169P | 2015-09-14 | 2015-09-14 | |
| US62/218,227 | 2015-09-14 | ||
| US62/218,169 | 2015-09-14 | ||
| PCT/US2016/051704 WO2017048824A1 (en) | 2015-09-14 | 2016-09-14 | COMPOSITIONS AND METHODS FOR TREATING CANCER VIA ANTAGONISM OF THE CD155/TIGIT PATHWAY AND TGF-β |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018531914A JP2018531914A (ja) | 2018-11-01 |
| JP2018531914A5 true JP2018531914A5 (OSRAM) | 2019-10-31 |
Family
ID=57121497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513505A Withdrawn JP2018531914A (ja) | 2015-09-14 | 2016-09-14 | ＣＤ１５５／ＴＩＧＩＴ経路およびＴＧＦ−βのアンタゴニストを介してがんを処置するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180251548A1 (OSRAM) |
| EP (1) | EP3349792A1 (OSRAM) |
| JP (1) | JP2018531914A (OSRAM) |
| AU (1) | AU2016322934A1 (OSRAM) |
| CA (1) | CA2998589A1 (OSRAM) |
| WO (1) | WO2017048824A1 (OSRAM) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8796443B2 (en) | 2008-09-22 | 2014-08-05 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
| CA2794187C (en) | 2010-03-24 | 2020-07-14 | Rxi Pharmaceuticals Corporation | Rna interference in ocular indications |
| KR20180044433A (ko) | 2010-03-24 | 2018-05-02 | 알엑스아이 파마슈티칼스 코포레이션 | 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭 |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| NZ753515A (en) | 2016-11-30 | 2022-02-25 | Oncomed Pharm Inc | Methods for treatment of cancer comprising tigit-binding agents |
| IL268554B2 (en) | 2017-02-08 | 2025-03-01 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CA3235295C (en) | 2017-02-20 | 2024-11-19 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| CN110621341A (zh) | 2017-04-26 | 2019-12-27 | 百时美施贵宝公司 | 使二硫键还原最小化的抗体生产方法 |
| LT3618863T (lt) | 2017-05-01 | 2023-10-10 | Agenus Inc. | Anti-tigit antikūnai ir jų panaudojimo būdai |
| WO2018204374A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| MA50661A (fr) * | 2017-05-02 | 2020-08-05 | Merck Sharp & Dohme | Formulations stables d'anticorps anti-tigit seuls et en association avec des anticorps du récepteur de mort programmée 1 (pd-1) et leurs procédés d'utilisation |
| BR112019025035A2 (pt) | 2017-06-01 | 2020-06-30 | Compugen Ltd. | método para tratar câncer |
| WO2018229163A1 (en) | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| IL322943A (en) | 2017-07-11 | 2025-10-01 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and their use |
| US20200215113A1 (en) * | 2017-08-07 | 2020-07-09 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides |
| WO2019037052A1 (zh) * | 2017-08-24 | 2019-02-28 | 深圳市博奥康生物科技有限公司 | 靶向沉默wucam的shrna |
| CN108558997B (zh) * | 2017-10-20 | 2021-10-08 | 中国人民解放军第四军医大学 | 一种重组融合蛋白TIGIT-Fc及其抗移植排斥反应的应用 |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
| US12384847B2 (en) | 2018-02-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen |
| US12215157B2 (en) | 2018-02-20 | 2025-02-04 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use |
| MX2020008795A (es) * | 2018-02-28 | 2020-10-08 | Yuhan Corp | Anti cuerpos anti tigit y usos de los mismos. |
| EP3765070A4 (en) | 2018-03-14 | 2021-12-15 | Dana-Farber Cancer Institute, Inc. | SPECIFICALLY MODIFIED CELLS, T-LYMPHOCYTE IMMUNE MODULATION ANTIBODIES AND THEIR USE PROCEDURES |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| MA53284A (fr) | 2018-08-08 | 2022-01-26 | Dragonfly Therapeutics Inc | Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur |
| JP2021534196A (ja) | 2018-08-23 | 2021-12-09 | シージェン インコーポレイテッド | 抗ｔｉｇｉｔ抗体 |
| KR102084196B1 (ko) * | 2018-08-29 | 2020-03-03 | 연세대학교 산학협력단 | 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| US11046769B2 (en) | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| US20220362333A1 (en) * | 2019-07-26 | 2022-11-17 | Board Of Trustees Of Michigan State University | Methods Of Preventing Or Treating Fatty Degeneration Of Skeletal Muscle |
| KR20220082007A (ko) * | 2019-10-08 | 2022-06-16 | 넥틴 테라퓨틱스 리미티드 | 폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도 |
| KR20220097443A (ko) * | 2019-11-05 | 2022-07-07 | 메르크 파텐트 게엠베하 | 암의 치료를 위한 PD-1, TGFβ 및 TIGIT의 조합 억제 |
| US20230057899A1 (en) | 2019-12-05 | 2023-02-23 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
| WO2021142088A1 (en) * | 2020-01-07 | 2021-07-15 | The Trustees Of The University Of Pennsylvania | Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies |
| WO2021216468A1 (en) * | 2020-04-19 | 2021-10-28 | Askgene Pharma Inc. | Human tigit specific single domain antibodies and methods of use |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| BR112022025801A2 (pt) | 2020-06-18 | 2023-10-03 | Hoffmann La Roche | Métodos para tratar um paciente e para tratar um paciente com escc avançado, kit, anticorpo, uso de um anticorpo e uso de um antagonista de ligação |
| CN111763660A (zh) * | 2020-08-07 | 2020-10-13 | 南京大学 | 一种重组溶瘤痘苗病毒及其制备方法和应用 |
| TW202246242A (zh) | 2021-01-15 | 2022-12-01 | 美商西健公司 | 免疫調節抗體藥物結合物 |
| CA3206244A1 (en) | 2021-02-03 | 2022-08-11 | Kung-Pern WANG | Immunostimulatory compounds and conjugates |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| CN113030487B (zh) * | 2021-03-31 | 2023-11-10 | 山东大学齐鲁医院 | Cd155在宫颈癌诊治中的应用 |
| TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法 |
| WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
| CN116003625A (zh) * | 2021-08-20 | 2023-04-25 | 中山康方生物医药有限公司 | 包含抗TIGIT抗体和TGF-βR的融合蛋白、其药物组合物及用途 |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| KR102680316B1 (ko) * | 2021-11-01 | 2024-07-01 | 오토텔릭바이오 주식회사 | 안티센스 올리고뉴클레오타이드 |
| MX2024011278A (es) | 2022-03-15 | 2024-09-25 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer. |
| CN115043910B (zh) * | 2022-03-25 | 2023-04-07 | 湖南中晟全肽生化有限公司 | 抑制tigit与cd155结合的多肽及其应用 |
| CA3252067A1 (en) | 2022-05-06 | 2023-11-09 | Seagen Inc. | Immunomodulatory Antibody-Drug Conjugates |
| AU2023284422A1 (en) | 2022-06-07 | 2024-12-19 | Genentech, Inc. | Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody |
| AU2023320054A1 (en) | 2022-08-03 | 2025-02-06 | Regents Of The University Of Minnesota | Immunostimulatory anti-pd-l1-drug conjugates |
| EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
| CN116284395B (zh) * | 2022-12-12 | 2024-11-08 | 合肥天港免疫药物有限公司 | 抗cd155的抗体及其应用 |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| EP3605088A1 (en) * | 2008-04-09 | 2020-02-05 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP6066732B2 (ja) * | 2010-03-05 | 2017-01-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 標的免疫調節抗体および融合タンパク質に基づく組成物および方法 |
| US8478258B2 (en) * | 2010-03-05 | 2013-07-02 | Intel Corporation | Techniques to reduce false detection of control channel messages in a wireless network |
-
2016
- 2016-09-14 US US15/758,090 patent/US20180251548A1/en not_active Abandoned
- 2016-09-14 CA CA2998589A patent/CA2998589A1/en not_active Abandoned
- 2016-09-14 JP JP2018513505A patent/JP2018531914A/ja not_active Withdrawn
- 2016-09-14 AU AU2016322934A patent/AU2016322934A1/en not_active Abandoned
- 2016-09-14 EP EP16778924.7A patent/EP3349792A1/en not_active Withdrawn
- 2016-09-14 WO PCT/US2016/051704 patent/WO2017048824A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531914A5 (OSRAM) | ||
| JP2023071876A (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| US11214615B2 (en) | Anti-TIM-3 antibodies and uses thereof | |
| US20170073414A1 (en) | Anti SIRP-alpha Antibodies and Bi-specific Macrophage Enhancing Antibodies | |
| JP2017537919A5 (OSRAM) | ||
| JP7459058B2 (ja) | Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法 | |
| JP2019513817A (ja) | Ｔｉｇｉｔに対する抗体 | |
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| JP2017535257A (ja) | 免疫応答およびがん治療の増強に使用するための組成物および方法 | |
| KR20160024391A (ko) | 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도 | |
| Schuster et al. | Immunotherapy with the trifunctional anti‐CD 20 x anti‐CD 3 antibody FBTA 05 (Lymphomun) in paediatric high‐risk patients with recurrent CD 20‐positive B cell malignancies | |
| JP2017532952A5 (OSRAM) | ||
| JP2015508072A5 (OSRAM) | ||
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| KR20200112913A (ko) | B7-h4 항체 및 그 사용 방법 | |
| JP2016538297A5 (OSRAM) | ||
| JP2013512278A5 (OSRAM) | ||
| JP2018516950A5 (OSRAM) | ||
| Abramson | Immunotherapy of multiple myeloma: promise and challenges | |
| Reichert et al. | 9th Annual European Antibody Congress, November 11–13, 2013, Geneva, Switzerland | |
| CN119053340A (zh) | 针对pd-l1和cd137的多特异性结合剂与抗pd-1抗体组合用于治疗癌症 | |
| JP2024536383A (ja) | 併用におけるｐｄ－ｌ１およびｃｄ１３７に対する多重特異性結合剤 | |
| US20200148758A1 (en) | Therapeutic combinations comprising eosinophil-depleting antibodies and uses thereof | |
| KR20250089556A (ko) | 면역관문 억제제 및 세포외 기질 성분 결합제 조합 요법 및 이의 사용 방법 | |
| RU2809243C2 (ru) | Антитела в7-н4 и способы их применения |